uniQure N.V. (QURE)
| Market Cap | 1.57B -52.4% |
| Revenue (ttm) | 18.67M +30.2% |
| Net Income | -252.21M |
| EPS | -4.04 |
| Shares Out | 69.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,513,332 |
| Open | 22.59 |
| Previous Close | 22.54 |
| Day's Range | 22.23 - 23.00 |
| 52-Week Range | 8.73 - 71.50 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 62.55 (+176.89%) |
| Est. Earnings | Nov 9, 2026 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for QURE stock is "Strong Buy." The 12-month stock price target is $62.55, which is an increase of 176.89% from the latest price.
News
uniQure downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded uniQure (QURE) to Equal Weight from Overweight with a price target of $28, down from $60. The firm sees increased uncertainty around for AMT-130 in Huntington’s disease following…
uniQure price target lowered to $48 from $65 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on uniQure (QURE) to $48 from $65 and keeps an Outperform rating on the shares. The firm is updating its…
uniQure price target lowered to $31 from $46 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on uniQure (QURE) to $31 from $46 and keeps a Neutral rating on the shares. The firm is updating its model following the…
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential s...
uniQure weakness creates attractive opportunity, says Wells Fargo
Wells Fargo reiterated an Overweight rating and $75 price target on uniQure (QURE). New four-year data on UHDRS, a secondary endpoint that appears confounded by the dynamics in the external…
RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’
RBC Capital analyst Luca Issi notes the uniQure (QURE) updated three-year data and reported first look at the four-year data for Huntington’s disease. The firm believes the data is clearly…
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law.
uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright
After uniQure (QURE) announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s disease, including outcomes for the 36-month and 48-m...
uniQure falls -38.4%
uniQure (QURE) is down -38.4%, or -$15.01 to $24.10.
uniQure falls -36.4%
uniQure (QURE) is down -36.4%, or -$14.23 to $24.88.
UniQure Insists Huntington's Drug Is Still on Track as Stock Plunges 48%
UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington's disease falls hort in a recent study.
uniQure Transcript: Study update
At 48 months, high-dose AMT-130 showed 61% TFC slowing and 44% cUHDRS slowing versus the updated control; the cUHDRS result was not statistically significant. The expanded 36-month analysis showed 80% cUHDRS and 67% TFC slowing.
uniQure Press release: Study update
uniQure issued a press release on September 29, 2026, disclosing material business information to investors.
uniQure Slides: Study update
uniQure has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
uniQure AMT-130 three-year data ‘continues to look robust,’ says Stifel
Stifel is reiterating a Buy rating on uniQure (QURE) after the company announced updated Phase 1/2 data for AMT-130 in Huntington’s disease. The three-year data, after including three additional patie...
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
UniQure , said on Tuesday its Huntington's treatment showed 44% slowing of disease progression, but did not reach statistical significance in an ongoing early-to-mid-stage trial.
uniQure announces additional data from studies of ifezuntirgene inilparvovec
uniQure (QURE) N.V. announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s disease. Outcomes for the 36-month and 48-month analys...
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed...
uniQure seeks US approval for Huntington's gene therapy after FDA reversal
Dutch gene therapy developer uniQure said on Wednesday it had applied for U.S. approval of its experimental treatment for Huntington's disease after the FDA reversed its earlier position on the drug,...
uniQure submits biologics license application to FDA for ifezuntirgene inilparvo
uniQure (QURE) announced the submission of a biologics license application, or BLA, to the FDA for the accelerated approval of ifezuntirgene inilparvovec, an investigational gene therapy for the treat...
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease
~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~ ~ Both submissions are supported by the three-year data analysis from the ...
uniQure resumed with an Outperform at William Blair
William Blair resumed coverage of uniQure (QURE) with an Outperform rating and $73 fair value estimate. The firm sees a “clearer pathway” to FDA approval for AMT-130 in Huntington’s disease.
uniQure price target lowered to $60 from $65 at Barclays
Barclays lowered the firm’s price target on uniQure (QURE) to $60 from $65 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2…
Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130
As previously reported, Wolfe Research upgraded uniQure (QURE) to Outperform from Peer Perform with a $65 price target The stock has priced in less than 50% odds of success for…
uniQure upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded uniQure (QURE) to Outperform from Peer Perform with a $65 price target